HEOYX
Price
$16.22
Change
-$0.48 (-2.87%)
Updated
Dec 18 closing price
RWIBX
Price
$62.66
Change
-$1.77 (-2.75%)
Updated
Dec 18 closing price
Ad is loading...

HEOYX vs RWIBX

Header iconHEOYX vs RWIBX Comparison
Open Charts HEOYX vs RWIBXBanner chart's image
Hartford Climate Opportunities Y
Price$16.22
Change-$0.48 (-2.87%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$62.66
Change-$1.77 (-2.75%)
VolumeN/A
CapitalizationN/A
HEOYX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
HEOYX vs. RWIBX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HEOYX is a Hold and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 121B vs. HEOYX (131M). RWIBX pays higher dividends than HEOYX: RWIBX (1.05) vs HEOYX (0.72). HEOYX was incepted earlier than RWIBX: HEOYX (9 years) vs RWIBX (23 years). HEOYX is a more actively managed with annual turnover of: 75.00 vs. RWIBX (27.00). RWIBX has a lower initial minimum investment than HEOYX: RWIBX (250) vs HEOYX (250000). RWIBX (11.34) and HEOYX (11.01) have marching annual gain over last year. HEOYX return over 5 years is better than : 51.59 vs. RWIBX (29.64).
HEOYXRWIBXHEOYX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years23 years-
Gain YTD8.5129.78187%
Front LoadN/AN/A-
Min. Initial Investment250000250100,000%
Min. Initial Investment IRAN/AN/A-
Net Assets131M121B0%
Annual Yield % from dividends0.721.0568%
Returns for 1 year11.0111.3497%
Returns for 3 years1.588.4119%
Returns for 5 years51.5929.64174%
Returns for 10 yearsN/A44.22-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics